Efficacy of ocrelizumab in relapsing multiple sclerosis Review article
Article Sidebar
Main Article Content
Abstract
Ocrelizumab is a humanized monoclonal antibody directed against the B-cell-specific cell-differentiation antigen CD20+, leading to a reduction in the number of B cells in the blood. This drug reduces the inflammatory response occurring in the course of multiple sclerosis, which clinically translates into a reduction in the progression of disability and radiological features of the demyelinating process. This suggests that activation of B lymphocytes plays an important role in the pathogenesis of multiple sclerosis. Based on the results of the ORATORIO study ocrelizumab, as the first drug in the world, was registered for the therapy of adult patients with early primary progressive form of multiple sclerosis. Based on a multicenter, randomized, double-blind, active comparator-controlled, phase III OPERA I and II trials, that showed lower levels of activity and disease progression in patients with relapsing multiple sclerosis receiving ocrelizumab compared with those treated with interferon β-1a, ocrelizumab was also registered for use in in this indication.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Kułakowska A., Bartosik-Psujek H., Hożejowski R. et al.: Selected aspects of the epidemiology of multiple sclerosis in Poland – a multicentre pilot study. Neurol. Neurochir. Pol. 2010; 44(5): 443-452.
3. Winkelmann A., Loebermann M., Reisinger E.C. et al.: Disease-modifying therapies and infectious risks in multiple sclerosis. Nat. Rev. Neurol. 2016; 12(4): 217-233.
4. Cree B.A., Gourraud P.A., Oksenberg J.R. et al.: Long-term evolution of multiple sclerosis disability in the treatment era. Ann. Neurol. 2016; 80(4): 499-510.
5. Martin F., Chan A.C.: B cell immunobiology in disease: evolving concepts from the clinic. Annu. Rev. Immunol. 2006; 24: 467-496.
6. Wekerle H.: B cells in multiple sclerosis. Autoimmunity 2017; 50(1): 57-60.
7. Klein C., Lammens A., Schäfer W. et al.: Response to: monoclonal antibodies targeting CD20. MAbs 2013; 5(3): 337-338.
8. Li R., Rezk A., Miyazaki Y. et al.: Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci. Transl. Med. 2015; 7(310): 310ra166.
9. DiLillo D.J., Hamaguchi Y., Ueda Y. et al.: Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J. Immunol. 2008; 180(1): 361-371.
10. Klein C., Lammens A., Schäfer W. et al.: Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 2013; 5(1): 22-33.
11. Baker D., Marta M., Pryce G. et al.: Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine 2017; 16: 41-50.
12. Frampton J.E.: Ocrelizumab: First Global Approval. Drugs 2017; 77(9): 1035-1041.